Health X Platform Limited: FY 2025-26 Performance and Restructuring Plan

Total Revenue stood at Rs 1,319.27 crore, while Net Profit reached Rs 1.18 crore.

Reader Takeaway: Profitability turnaround and strategic business focus consolidation are positive, though subsidiary liquidity risks persist.

What just happened

Health X Platform Limited, formerly Sastasundar Ventures Limited, has reported its financial results for the year ended March 31, 2026. The company achieved a consolidated revenue of Rs 1,319.27 crore, up from Rs 1,110.95 crore in the prior year. The firm posted a net profit of Rs 1.18 crore, a significant improvement from the Rs 91.17 crore net loss recorded in FY 2024-25. The board also approved a comprehensive restructuring plan to spin off its financial services arm and integrate Sastasundar Healthbuddy Limited into the main business.

Why this matters

The restructuring aims to bifurcate the company’s diverse interests into two distinct channels: a pure-play healthcare entity and a separate financial services vehicle. This is expected to streamline operational focus and potentially unlock value for shareholders. The return to profitability serves as a critical indicator that the underlying e-pharmacy and healthcare business model is scaling effectively.

The backstory

Historically known as Sastasundar Ventures, the entity has been aggressively pivoting toward the digital healthcare space. The latest move to demerge the financial services business into Microsec Resources Private Limited (MRPL) is the culmination of efforts to isolate non-core legacy operations and concentrate capital on the healthcare vertical.

Risks to watch

Auditors have flagged a material uncertainty regarding the going concern status of Genu Path Labs Limited (GPL), a step-down subsidiary, citing that accumulated losses have exceeded its current assets. Additionally, the company recently paid an Rs 8 lakh penalty to the Registrar of Companies for legacy non-compliance issues. The highly competitive e-pharmacy landscape remains a persistent margin pressure point.

Context metrics

Consolidated EBITDA improved to Rs 6.15 crore for FY 2025-26, compared to Rs 3.81 crore in the previous fiscal year. The company opted not to declare a dividend for the current reporting period.

What to track next

Investors should closely follow the progression of the NCLT and regulatory approval process for the composite scheme of arrangement. Additionally, updates on the operational liquidity and financial stability of the subsidiary Genu Path Labs will be critical for gauging long-term balance sheet health.